Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glyceryl trinitrate, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenylephrine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium metabisulfite; nitrogen; sodium chloride; citric acid - indications as at 01 jan 1991 : phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, of hypersensitivity. it is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - acetazolamide, quantity: 250 mg - tablet, uncoated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; sodium starch glycollate - for adjunctive treatment of oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open angle) glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg/g - cream - excipient ingredients: sodium hydroxide; stearyl alcohol; lactic acid; cetyl esters wax; purified water; chlorhexidine hydrochloride; sorbitan monostearate; octyldodecanol; glycerol; polysorbate 60; cetyl alcohol - indications as at 18 december 2001. vulvo-vaginal complaints due to oestrogen deficiency associated with the climacteric and the postmenopause or after ovariectomy: atrophic vaginitis. puritis vulvae. dyspareunia due to vulvo-vaginal atrophy. as auxiliary therapy in the treatment of vaginal infections. as pre-operative therapy for vulvo-vaginal surgery and during subsequent convalescence. ulcers in the case of prolapse of the uterus or vagina. to avoid misinterpretation of a cytological smear.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; indigo carmine; oxidised maize starch; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate; propylene glycol; water for injections; ethanol - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - hydrochlorothiazide, quantity: 50 mg; amiloride hydrochloride dihydrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; lactose monohydrate; maize starch; guar gum; sunset yellow fcf; pregelatinised maize starch; magnesium stearate - indicated in the treatment of patients with oedema of cardiac origin; hepatic cirrhosis with ascites; hypertension in whom potassium depletion might be anticipated. moduretic, with its combination of amiloride hcl and hydrochlorothiazide, minimises the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. moduretic, with its built-in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important. moduretic may be used alone, or as an adjunct to other antihypertensive drugs. since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of excessive drop in blood pressure.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

ge healthcare iits australia pty ltd -